李疆主治醫(yī)師
中山大學(xué)附屬腫瘤醫(yī)院生物治療中心
教育經(jīng)歷(按時(shí)間倒排序)： 1999/9 - 2002/7，中山大學(xué)，博士，導(dǎo)師：張清炯 1992/9 - 1995/7，中山醫(yī)科大學(xué)，碩士，導(dǎo)師：曾瑞萍 1987/9 - 1992/7，重慶醫(yī)科大學(xué)，臨床醫(yī)學(xué)系，學(xué)士 工作經(jīng)歷(科研與學(xué)術(shù)工作經(jīng)歷，按時(shí)間倒排序)： 2015/1 - 至今， 中山大學(xué)，腫瘤防治中心，生物治療中心，研究員 2006/01-2014//12， 中山大學(xué)，腫瘤防治中心，生物治療中心，副研究員 2008/11-2010/03, 美國(guó)Bylor College of Medicine，Center for Cell and Gene Therapy(Rong-Fu Wang實(shí)驗(yàn)室)，博士后 2004/09-2005/03, 瑞典Karolinska大學(xué)微生物與腫瘤生物學(xué)中心Maria G Masucci教授課題組, 訪問(wèn)學(xué)者 2002/07-2005/12， 中山大附屬腫瘤醫(yī)院，生物治療中心，助理研究員 1995/07-1999/09, 廣東省人民醫(yī)院老年醫(yī)學(xué)研究所，助理研究員。 主持或參加科研項(xiàng)目及人才計(jì)劃項(xiàng)目情況(按時(shí)間倒排序)： 1、國(guó)家自然科學(xué)基金面上項(xiàng)目，81572982、EBV-LMP1上調(diào)鼻咽癌Warburg效應(yīng)在腫瘤相關(guān)免疫細(xì)胞分化與功能調(diào)節(jié)中的作用和機(jī)制。2016/01-2019/12、55萬(wàn)、主持 2、國(guó)家自然科學(xué)基金面上項(xiàng)目，81372442、髓源性抑制細(xì)胞(MDSC)參與鼻咽癌免疫耐受的作用和調(diào)控機(jī)制、2014//01-2017/12、75萬(wàn)元、在研、主持。 3、國(guó)家自然科學(xué)基金面上項(xiàng)目，81172164、癌細(xì)胞分泌exosome改變CTL細(xì)胞功能導(dǎo)致鼻咽癌免疫逃逸的機(jī)制研究、20012/01-2014/12、55萬(wàn)元、在研、主持。 4、國(guó)家自然科學(xué)基金面上項(xiàng)目，30872981、調(diào)節(jié)性T淋巴細(xì)胞(Treg)與鼻咽癌免疫逃逸機(jī)理和臨床相關(guān)性的研究、2008/01-2011/12、30萬(wàn)元、結(jié)題、主持。 近五年文章： [1] Li ZL, Ye SB, OuYang LY, Zhang H, Chen YS, He J, Chen QY, Qian CN, Zhang XS, Cui J, Zeng YX, Li J. COX-2 promotes metastasis in nasopharyngeal carcinoma by mediating interactions between cancer cells and myeloid-derived suppressor cells. Oncoimmunology. 2015 Jul 9;4(11):e1044712. eCollection 2015 Nov. (IF = 6.26)(通訊作者)[2] Li J#, Chen QY#, He J, Li ZL, Tang XF, Chen SP, Xie CM, Li YQ, Huang LX, Ye SB, Ke ML, Tang LQ, Liu H, Zhang L, Guo SS, Xia JC, Zhang XS, Zheng LM, Guo X, Qian CN, Mai HQ*, Zeng YX*.Phase I Trial of Adoptively Transferred Tumor-infiltrating Lymphocyte Immunotherapy Following ConcurrentChemoradiotherapy in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma. Oncoimmunology. 2015.Mar 6; 2(4):e976507. (第一作者) (IF = 6.26)[3].Ye SB, Li ZL, Luo DH, Huang BJ, Chen YS, Zhang XS, Cui J, ZengYX,Li J*.Tumor-derived exosomes promote tumor progression and T-cell dysfunction throughthe regulation of enriched exosomal microRNAs in human nasopharyngeal carcinoma. Oncotarget. 2014 Jul 30;5(14):5439-52.(IF = 6.67)(通訊作者)[4]. OuYang LY#, Wu XJ#, Ye SB, Zhang RX, Li ZL, Liao W, Pan ZZ, Zheng LM, Zhang XS, Wang Z, Li Q, Ma G*, Li J*. Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer. JTransl Med. 2015 Feb 1;13(1):47. (IF = 3.99)(通訊作者)[5]. Zhang L#, Ye SB#, Li ZL, Ma G, Chen SP, He J, Liu WL, Xie D, Zeng YX, Li J*.Increased HIF-1alpha expression in tumor cells and lymphocytes of tumormicroenvironments predicts unfavorable survival in esophageal squamous cellcarcinoma patients. Int J ClinExpPathol. 2014 Jun 15;7(7):3887-97.(IF =1.78)(通訊作者)[6]. Zhang L#, Ye SB#, Ma G, Tang XF, Chen SP, He J, Liu WL, Xie D, Zeng YX, Li J*.The expressions of MIF and CXCR4 protein in tumor microenvironment are adverseprognostic factors in patients with esophageal squamous cell carcinoma. J Transl Med. 2013 Mar 8;11:60.(IF = 3.99)(通訊作者)[7].Li J#*, Mo HY#, Xiong G, Zhang L, He J, Huang ZF, Liu ZW, Chen QY, Du ZM, Zheng LM, Qian CN*, Zeng YX. Tumor microenvironment MIF directs the accumulation of IL-17-producing tumor-infiltrating lymphocytes and predicts favorable survival in nasopharyngeal carcinoma patients. J Biol Chem. 2012 Oct 12;287(42):35484-95.(第一，通訊作者)(IF=4.67)[8]. He J, Tang XF, Chen QY, Mai HQ, Huang ZF, Li J*, Zeng YX. Ex vivo expansion of tumor-infiltrating lymphocytes from nasopharyngeal carcinoma patients for adoptive immunotherapy. Chin J Cancer. 2012 Jun;31(6):287-94.(通訊作者)[9].Li J*, Huang ZF, Xiong G, Mo HY, Qiu F, Mai HQ, Chen QY, He J, Chen SP, Zheng LM, Qian CN, Zeng YX. Distribution, characterization, and induction of CD8+ regulatory T cells and IL-17-producing CD8+ T cells in nasopharyngeal carcinoma.JTransl Med. 2011 Nov 4;9(1):189.(第一，通訊作者)(SCI, IF=3.4740(2011))[10]. Peng RJ, Huang ZF, Zhang YL, Yuan ZY, Xia Y, Jiang WQ, Zeng YX*, Li J*. Circulating and Tumor-Infiltrating Foxp3 Regulatory T Cell Subset in Chinese Patients with Extranodal NK/T Cell Lymphoma. Int J Biol Sci. 2011;7(7):1027-36.(通訊作者)(SCI, IF=4.3)[11].Li J#, Chen QY#, Mo H, Zhang YL, Huang ZF, Zeng YX*. Immunophenotyping at the time of diagnosis distinguishes two groups of nasopharyngeal carcinoma patients: implications for adoptive immunotherapy. Int J Biol Sci. 2011;7(5):607-17.(第一作者)(IF=4.3)[12]. Zhang YL#, Li J#(共同第一作者), Mo HY, Qiu F, Zheng LM, Qian CN, Zeng YX*. Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways. Mol Cancer. 2010 Jan 10; 9: 4.(第一作者是申請(qǐng)人的碩士研究生)(IF=5.3) 更新時(shí)間：2015.10.21
惡性腫瘤T淋巴細(xì)胞免疫治療及惡性腫瘤免疫逃逸的相關(guān)機(jī)制研究。?
張建波主任醫(yī)師
河南省腫瘤醫(yī)院 · 病理科門(mén)診
擅長(zhǎng)：惡性腫瘤T淋巴細(xì)胞免疫治療及惡性腫瘤免疫逃逸的相關(guān)機(jī)制研究。?
